Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery.

OBJECTIVES Although clinicians recognize hip involvement, which frequently leads to hip replacement surgery, as an important feature of AS, data on the epidemiology, nature of the disease and therapeutic strategies are scarce. We aimed to describe the epidemiology of clinical and radiological hip involvement and define the risk factors for the hip replacement surgery in AS patients. METHODS Data from 3 datasets were merged, including 847 Belgian (ASPECT database), 1405 Spanish (REGISPONSER database) and 466 Ibero-American (RESPONDIA database) AS patients. The ASPECT and REGISPONSER database (Dataset A) are used for exploratory analysis; the RESPONDIA database (Dataset B) is used for confirmative analysis. Factors associated with hip involvement and the hip replacement surgery were analysed. RESULTS Twenty four (REGISPONSER) to 36% (RESPONDIA) of AS patients under rheumatologist's care presented clinical hip involvement, including the 5% (Dataset A) of AS patients who needed hip replacement surgery. Patients with hip involvement had significantly worse overall Bath Ankylosing Spondylitis Functional Index (BASFI) scores compared with patients without hip involvement (mean difference = 1.6, P < 0.001) (Dataset A, confirmed in B). Corrected for disease duration, patients with early disease onset, enthesial and axial disease needed most frequently hip replacement surgery (Dataset A, confirmed in B). CONCLUSION Hip involvement is commonly recognized by rheumatologists in AS patients, and involves about one out of the three to four patients with AS and is associated with impaired functioning reflected by higher overall BASFI scores. Early onset of disease, axial and enthesial disease are associated with the hip replacement surgery in AS.

[1]  L. Carmona,et al.  Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. , 2007, Rheumatology.

[2]  J. Reveille,et al.  Clinical, radiographic and functional differences between juvenile-onset and adult–onset ankylosing spondylitis: results from the PSOAS cohort , 2007, Annals of the rheumatic diseases.

[3]  A. Boonen,et al.  The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice , 2007, Annals of the rheumatic diseases.

[4]  K. Pile,et al.  Development and validation of a simple tape-based measurement tool for recording cervical rotation in patients with ankylosing spondylitis: comparison with a goniometer-based approach. , 2006, The Journal of rheumatology.

[5]  A. Boonen A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis , 2006, Nature Clinical Practice Rheumatology.

[6]  A. Boonen,et al.  The burden of ankylosing spondylitis. , 2006, The Journal of rheumatology. Supplement.

[7]  H. Stein,et al.  Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. , 2006, Arthritis and rheumatism.

[8]  G. Verbruggen Chondroprotective drugs in degenerative joint diseases. , 2006, Rheumatology.

[9]  P. Andlin-Sobocki,et al.  Costs and quality of life of patients with ankylosing spondylitis in Canada. , 2006, The Journal of rheumatology.

[10]  S. van der Linden,et al.  Factors associated with body function and disability in patients with ankylosing spondylitis: a cross-sectional study. , 2003, The Journal of rheumatology.

[11]  A. Calin,et al.  The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis. , 2003, The Journal of rheumatology.

[12]  A. Calin,et al.  Predictors of longterm outcome in ankylosing spondylitis. , 2003, The Journal of rheumatology.

[13]  P. Brophy Axoglial junctions: Separate the channels or scramble the message , 2001, Current Biology.

[14]  A. Calin,et al.  The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. , 1998, Arthritis and rheumatism.

[15]  M. Dougados,et al.  Predictive factors for the longterm outcome of spondyloarthropathies. , 1994, The Journal of rheumatology.

[16]  A Calin,et al.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.

[17]  Alan Agresti,et al.  Categorical Data Analysis , 2003 .

[18]  S. Goemaere,et al.  Destructive hip lesions in seronegative spondyloarthropathies: relation to gut inflammation. , 1990, The Journal of rheumatology.

[19]  A. Calin,et al.  The relationship between pelvic, spinal and hip involvement in ankylosing spondylitis--one disease process or several? , 1988, British journal of rheumatology.

[20]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[21]  K. Hardinge,et al.  Clinical and radiographic features of spondylitic hip disease. , 1979, Annals of the rheumatic diseases.

[22]  H. Mielants,et al.  Agreement between evidence and Belgian rheumatologists' experience on the use of DMARDs for arthritis and/or enthesitis in ankylosing spondylitis , 2008 .

[23]  C. Liu,et al.  Sulfasalazine in Ankylosing Spondylitis , 2005, The Cochrane database of systematic reviews.

[24]  C. Liu,et al.  Methotrexate for ankylosing spondylitis. , 2004, The Cochrane database of systematic reviews.

[25]  Luis A. Escobar,et al.  Statistical Intervals: A Guide for Practitioners , 1991 .